Predictive Oncology Inc

Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes clinical testing and contract research services that include the application of AI. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within corporate. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Eagan, MN.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Predictive Oncology Inc advances in cancer research and cost optimization

POAI's Q2 2024 performance reflects progress in research, technology, and cost optimization strategies.
While facing challenges in financial metrics, the company's focus on innovation and shareholder value creation positions it for long-term success.
Opportunities lie in leveraging AI capabilities, strategic partnerships, and revenue growth initiatives to drive future growth and sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes contract services that include the application of AI, partnering projects, and clinical testing. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within the Corporate segment. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Pittsburgh, PA.

PITTSBURGH, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, is scheduled to deliver a virtual presentation and host investor one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held September 9th through 11th in New York, NY.

Predictive Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Predictive Oncology Inc. (NASDAQ:POAI ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Glenn Garmont – Investor Relations Raymond Vennare – Chairman and Chief Executive Officer Josh Blacher – Chief Financial Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Second Quarter 2024 Earnings Conference Call.

Predictive Oncology Inc. (POAI) Q2 2024 Earnings Call Transcript

Company to host investor call and webcast today, August 14th, at 8:30am EDT Company to host investor call and webcast today, August 14th, at 8:30am EDT

Predictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business Update

PITTSBURGH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the second quarter ended June 30, 2024 before the markets open on Wednesday, August 14, 2024. The company will host a corporate update conference call and live audio webcast at 8:30 a.m.

Predictive Oncology to Report Second Quarter 2024 Financial Results on Wednesday, August 14, 2024

PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 958,117 shares of its common stock having a current exercise price of $14.00 originally issued in February 2021, June 2021 and May 2022, at a reduced exercise price of $1.32 per share. The issuance and/or resale of the shares of common stock issuable upon exercise of the existing warrants, as applicable, are registered pursuant to effective registration statements on Form S-1 (File No. 333-267689), Form S-3 (File No. 254309) and Form S-3 (333-255582). The gross proceeds to Predictive Oncology from the exercise of the existing warrants are expected to be approximately $1.26 million, prior to deducting placement agent fees and transaction expenses payable by the Company.

Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds

Shares of biotechnology specialist Predictive Oncology (NASDAQ: POAI ) — which leverages artificial intelligence (AI) and machine learning models for the discovery of novel biomarkers in cancer research protocols — soared on Thursday. Earlier, the company announced a major development in terms of the predictability models of ovarian cancer.

Why Is Predictive Oncology (POAI) Stock Up 70% Today?

Expands AI/ML driven offering to include novel oncology biomarker discovery to predict patient outcomes and drug response in oncology

Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results

Company files expansive intellectual property protection for “Membrane Protein Factory” to produce purified and biologically active membrane proteins for drug development

Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)

Predictive Oncology's organ-specific in vitro models are designed to better mimic  the physiological environment of human tissue

Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery

Presentation to highlight Company's novel application of AI/machine learning capabilities utilizing its proprietary biobank of more than 150,000 tumor samples to guide leading biopharma partners through early oncologic drug discovery Presentation to highlight Company's novel application of AI/machine learning capabilities utilizing its proprietary biobank of more than 150,000 tumor samples to guide leading biopharma partners through early oncologic drug discovery

Predictive Oncology Announces CEO Raymond Vennare to Present at the BIO International Convention 2024

Study successfully demonstrated Predictive's ability to build AI multi-omic machine learning models to predict survival outcomes among ovarian cancer patients better than clinical data alone Study successfully demonstrated Predictive's ability to build AI multi-omic machine learning models to predict survival outcomes among ovarian cancer patients better than clinical data alone

Predictive Oncology Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Predictive Oncology Inc. (NASDAQ:POAI ) Q1 2024 Earnings Call Transcript May 15, 2024 8:30 AM ET Company Participants Glenn Garmont - IR Raymond Vennare - CEO and Chairman Josh Blacher - CFO Operator Ladies and gentlemen, good morning, and thank you for standing by. Welcome to the Predictive Oncology Q1 2024 Earnings Conference Call.

Predictive Oncology Inc. (POAI) Q1 2024 Earnings Call Transcript

Company to host investor call and webcast today, May 15th, at 8:30am EDT Company to host investor call and webcast today, May 15th, at 8:30am EDT

Predictive Oncology Reports First Quarter 2024 Financial Results and Provides Business Update

PITTSBURGH, May 10, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the first quarter ended March 31, 2024 before the markets open on Wednesday, May 15, 2024. The company will host a corporate update conference call and live audio webcast at 8:30 a.m.

Predictive Oncology to Report First Quarter 2024 Financial Results on Wednesday, May 15, 2024

Guardforce AI Co Ltd

Inuvo

Everyone's current favorite antagonist, Federal Reserve Chair Jerome Powell, might be turning the tide with his latest comment on the economy. In a recent address, He stated, “I don't see the ‘stag' or the ‘flation',” dispelling concerns about a 1970s-like stagflation.

The 3 Most Undervalued AI Penny Stocks to Buy in May 2024

ParaZero Technologies Ltd

SoundHound AI Inc

Artificial intelligence has fueled the stock market over the last 12 to 15 months. Many have suggested that its emergence alone is the reason the economy did not collapse in 2023 and remains strong today.

AI-Fueled Penny Stocks: 3 High-Risk, High-Reward Opportunities

PITTSBURGH, April 24, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that an abstract has been accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held May 31-June 4, 2024, in Chicago, Il.

Predictive Oncology Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Rekor Systems Inc

Artificial intelligence is a big business and it will likely get bigger, possibly boding well for AI penny stocks. While extremely speculative, these ideas present enormous upside potential.

3 AI Penny Stocks With Massive Growth Potential: April Edition

Predictive Oncology Inc. (POAI) Q4 2023 Earnings Call Transcript

Company to host investor call and webcast on Monday, April 1st, at 8:30am EDT Company to host investor call and webcast on Monday, April 1st, at 8:30am EDT

Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update

PITTSBURGH, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that Raymond F. Vennare, Chief Executive Officer, will participate in three upcoming investor conferences. Please see below for additional details about the events and how to request a one-on-one meeting with management.

Predictive Oncology to Participate in Upcoming Investor Conferences

Artificial intelligence and penny stocks don't necessarily go together like peanut butter and jelly, but there is some allure to AI penny stocks for risk-tolerant investors.   In 2023, companies were bending over backward to announce their AI bona fides.

3 Penny Stocks That Will Be the Surefire AI Winners of Tomorrow

PITTSBURGH, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that Raymond F. Vennare, Chief Executive Officer, will present at the upcoming Biotech Showcase, in San Francisco, CA, on January 9, 2024, at 4:00 p.m. PT. Company management will also participate in the 13th Annual LifeSci Partners Corporate Access Event and BIO Partnering @ JPM Week 2024. Please see below for additional details about the events and how to request a one-on-one meeting with management.

Predictive Oncology to Participate in Upcoming San Francisco Conferences

Predictive Oncology Inc. (NASDAQ:POAI ) Q3 2023 Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Glenn Garmont - IR Raymond Vennare - CEO and Chairman Josh Blacher - CFO Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Q3 2023 Earnings Conference Call.

Predictive Oncology Inc. (POAI) Q3 2023 Earnings Call Transcript

Predictive Oncology Inc. (NASDAQ:POAI) listed a number of recent milestones with the release of its third-quarter results, which also revealed a significant 22% reduction in its net loss. Chairman and CEO Raymond Vennare highlighted the delivery of successful results from its first campaign with Cancer Research Horizons, a subsidiary of the largest independent funder of cancer research in the world.

News for Predictive Oncology Inc Stock (POAI)